Trial Profile
A Phase I Open-label, Multicenter, Dose-escalating Study of Radium-223 in Patients With Advanced Skeletal Metastases
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 May 2017
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Bone metastases
- Focus Adverse reactions; First in man
- Sponsors Bayer
- 06 May 2015 New trial record